N-Terminal Peptide of PGLYRP1/Tag7 Is a Novel Ligand for TREM-1 Receptor

Sharapova, Tatiana N.; Ivanova, Olga K.; Romanova, Elena A.; Sashchenko, Lidia P.; Yashin, Denis V.

doi:10.3390/ijms23105752

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

N-Terminal Peptide of PGLYRP1/Tag7 Is a Novel Ligand for TREM-1 Receptor

and

Laboratory of Molecular Immunogenetics of Cancer, Institute of Gene Biology RAS, 111394 Moscow, Russia

Author to whom correspondence should be addressed.

Academic Editors: Nunzianna Doti and Menotti Ruvo

Int. J. Mol. Sci. 2022, 23(10), 5752; https://doi.org/10.3390/ijms23105752

Received: 6 May 2022 / Revised: 17 May 2022 / Accepted: 19 May 2022 / Published: 20 May 2022

(This article belongs to the Special Issue Synthetic Peptides and Peptidomimetics: From Basic Science to Biomedical Applications—2nd Edition)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

An investigation of innate immunity receptors sheds light on the mechanisms of inflammation and associated immune reactions. One of the key immune regulators is the TREM-1 receptor, which is involved in both inflammation and antitumor immune response. In this article, we have obtained a new ligand for the TREM-1 receptor. The peptide, named N3, is a part of the innate immune protein PGLYRP1/Tag7. It is responsible for activating the TREM-1 signaling pathway. Here, we have demonstrated that the N3 peptide acts like other TREM-1 receptor ligands: its binding results in a mild inflammation response and appearance of cytotoxic lymphocytes. We have shown that cytotoxic populations of lymphocytes in N3 peptide-treated PBMCs are similar to those treated with Tag7 or Hsp70. We also determined the part of the N3 peptide responsible for binding to TREM-1. The resulting peptide (N9) consists of nine amino acids and can be considered as a potential peptide that blocks TREM-1 signaling. View Full-Text

Keywords: TREM-1; peptides; PGLYRP1/PGRP-S/Tag7; cytotoxicity; cytokines

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 49 KiB)

Share and Cite

MDPI and ACS Style

Sharapova, T.N.; Ivanova, O.K.; Romanova, E.A.; Sashchenko, L.P.; Yashin, D.V. N-Terminal Peptide of PGLYRP1/Tag7 Is a Novel Ligand for TREM-1 Receptor. Int. J. Mol. Sci. 2022, 23, 5752. https://doi.org/10.3390/ijms23105752

AMA Style

Sharapova TN, Ivanova OK, Romanova EA, Sashchenko LP, Yashin DV. N-Terminal Peptide of PGLYRP1/Tag7 Is a Novel Ligand for TREM-1 Receptor. International Journal of Molecular Sciences. 2022; 23(10):5752. https://doi.org/10.3390/ijms23105752

Chicago/Turabian Style

Sharapova, Tatiana N., Olga K. Ivanova, Elena A. Romanova, Lidia P. Sashchenko, and Denis V. Yashin. 2022. "N-Terminal Peptide of PGLYRP1/Tag7 Is a Novel Ligand for TREM-1 Receptor" International Journal of Molecular Sciences 23, no. 10: 5752. https://doi.org/10.3390/ijms23105752

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

N-Terminal Peptide of PGLYRP1/Tag7 Is a Novel Ligand for TREM-1 Receptor

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI